318 related articles for article (PubMed ID: 32528479)
1. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
Front Immunol; 2020; 11():1008. PubMed ID: 32528479
[TBL] [Abstract][Full Text] [Related]
2.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
3. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
[TBL] [Abstract][Full Text] [Related]
5. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
6. A robust platform for expansion and genome editing of primary human natural killer cells.
Huang RS; Lai MC; Shih HA; Lin S
J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33433623
[TBL] [Abstract][Full Text] [Related]
7. Optical Control of Genome Editing by Photoactivatable Cas9.
Otabe T; Nihongaki Y; Sato M
Methods Mol Biol; 2021; 2312():225-233. PubMed ID: 34228293
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 in genome editing: Its function and medical applications.
Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 genome engineering of primary CD4
Hultquist JF; Hiatt J; Schumann K; McGregor MJ; Roth TL; Haas P; Doudna JA; Marson A; Krogan NJ
Nat Protoc; 2019 Jan; 14(1):1-27. PubMed ID: 30559373
[TBL] [Abstract][Full Text] [Related]
10. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes.
Jacobi AM; Rettig GR; Turk R; Collingwood MA; Zeiner SA; Quadros RM; Harms DW; Bonthuis PJ; Gregg C; Ohtsuka M; Gurumurthy CB; Behlke MA
Methods; 2017 May; 121-122():16-28. PubMed ID: 28351759
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
12. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9-Mediated Gene Silencing in Cultured Human Epithelia.
Gago S; Overton NLD; Bowyer P
Methods Mol Biol; 2021; 2260():37-47. PubMed ID: 33405030
[TBL] [Abstract][Full Text] [Related]
14. Genome editing via delivery of Cas9 ribonucleoprotein.
DeWitt MA; Corn JE; Carroll D
Methods; 2017 May; 121-122():9-15. PubMed ID: 28410976
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of Cas9 and single-guided RNAs in
Qiao J; Li W; Lin S; Sun W; Ma L; Liu Y
Commun Biol; 2019; 2():161. PubMed ID: 31069270
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas systems: ushering in the new genome editing era.
Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
[TBL] [Abstract][Full Text] [Related]
17. Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers.
Jain S; Xun G; Abesteh S; Ho S; Lingamaneni M; Martin TA; Tasan I; Yang C; Zhao H
ACS Synth Biol; 2021 Jun; 10(6):1320-1327. PubMed ID: 34006094
[TBL] [Abstract][Full Text] [Related]
18. Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays.
Kurata M; Wolf NK; Lahr WS; Weg MT; Kluesner MG; Lee S; Hui K; Shiraiwa M; Webber BR; Moriarity BS
PLoS One; 2018; 13(9):e0198714. PubMed ID: 30222773
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 in Genome Editing and Beyond.
Wang H; La Russa M; Qi LS
Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
[TBL] [Abstract][Full Text] [Related]
20. Guide RNA engineering for versatile Cas9 functionality.
Nowak CM; Lawson S; Zerez M; Bleris L
Nucleic Acids Res; 2016 Nov; 44(20):9555-9564. PubMed ID: 27733506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
